Ultragenyx gets FDA approval for Fayuvi in Sanfilippo A
FDA approved Ultragenyx’s Fayuvi for children with Sanfilippo syndrome type A, following a 13% stock gain to $14.50 at Thursday’s close.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.